how do you know which cryptocurrency to buy See results about

Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.Saudi institutions are optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology. Ekta Torani, chief investment officer of Saudi KBW Venture Capital Company, recently said in Abu Dhabi, United Arab Emirates that with the increasingly close economic and trade ties between the Gulf region and China, the institution is optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology.Some short-term inter-bank bonds performed brilliantly. The yield of 2-year active bonds "21 interest-bearing bonds 02" went down 5bp to reach 1.1%, which was 11bp upside down from the current 1-year active bonds "24 discount bonds 67" yield of 1.21%.

Zhonglu Co., Ltd.: The total amount of taxes and late fees paid is 15,430,100 yuan. Zhonglu Co., Ltd. announced that the company, as a limited partner of Zhonglu Advantage, received its cash asset distribution according to the resolution of Zhonglu Advantage Partner Meeting. In view of the above-mentioned asset allocation matters, the company strictly abides by the relevant regulations and adopts the principle of "tax after distribution". As required, it has declared and paid enterprise income tax of 11,770,500 yuan and late payment fee of 3,659,500 yuan, totaling 15,430,100 yuan. The late payment fee paid by the company will be included in the current profit and loss in 2024, which is expected to affect the company's net profit attributable to shareholders of listed companies in 2024 by about 3,659,500 yuan.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.According to the local government, Russia attacked the energy facilities in the Lviv region in western Ukraine.

Report: By 2035, the demand for hydrogen in the global power industry may increase fourfold. According to analysis, the demand for clean hydrogen in the global power industry will reach 4 million tons by 2035. This is five times the scale of 800,000 tons of clean hydrogen agreements signed by the power industry at present. The power industry is increasingly interested in hydrogen, which is good news for hydrogen producers who are competing to find an off-buyer. However, from the climate point of view, the prospect is not so optimistic, because most global reserve projects plan to burn hydrogen and natural gas together.Japanese Prime Minister's Assistant: Japan must be prepared for Trump to impose tariffs. Japanese Prime Minister's Assistant Akihisa Nagashima said that Japan needs to be prepared for US President-elect Trump's threat to impose tariffs on China, Canada and Mexico, and adjust the supply chain to reduce the collateral damage suffered by Japanese enterprises. In an interview with the media on Thursday, Akihisa Nagashima said that he had "frank" communication with Trump team members on tariff issues during his recent visit to the United States. "I realized that Japan must be ready for Trump to implement his plan," he said. Akihisa Nagashima said that these tariff measures may encourage Japan to reduce its dependence on these three countries, where some Japanese companies operate and parts made in Japan are transported to these three countries to manufacture finished products for export to the United States. "Japanese companies will certainly try to restructure the supply chain," he pointed out. "This is economically reasonable." (Interface News)The real estate sector fluctuated and fell, and many shares such as gemdale fell by more than 5%. Qixia Construction once approached the daily limit, and many shares such as gemdale, Everbright Jiabao, Urban Construction Development, Shoukai Shares and Greenland Holdings fell by more than 5%.